Is Eli Lilly Stock a Buy?
Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and will continue to order them through good times and more difficult times as well. But Lilly also is bringing investors another element that isn't as common in the industry -- and that's explosive growth.
This is thanks to the company's development of treatments in an area that's in high demand and is forecast to continue along this path throughout the decade. I'm talking about weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for patients aiming to shed pounds. Both of these products quickly became blockbusters and, along with drugs from Novo Nordisk, dominate the market.
All of this has helped Lilly's revenue climb in the double digits in recent quarters and the stock price to take off. The shares have advanced more than 200% over the past three years. Now the question is: Is it too late to get in on this weight loss giant, or is Lilly stock still a buy? Let's find out.
Source Fool.com
